| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514900600 | Epidermal growth factor (EGF) or epidermal growth factor-like or derivative | 43 |
| 20100286043 | USE OF NEUREGULIN-1 IN REDUCING BRAIN DAMAGE - Methods of reducing and/or protecting against disorders in perinatal subjects are disclosed. Such methods can be used for disorders associated with neuronal cell damage. In certain aspects, the method comprises administering a therapeutically effective amount of neuregulin or a biologically active analog with a pharmaceutical carrier to a perinatal subject. In addition, the perinatal subject can be a fetus where the neuregulin is administered to the pregnant mother. Methods for assessing whether a perinatal subject is at risk for developing a neurological disorder are also disclosed. For example, expression levels of neuregulin can be used as an indication the perinatal subject is at risk for developing a disorder associated with neuronal cell damage. Evaluating the genotype of the NRG locus in a perinatal subject can also be used as an indicator of the risk of developing neurological disorders. | 11-11-2010 |
| 20110009319 | CRIPTO ANTAGONISM OF ACTIVIN AND TGF-B SIGNALING - Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b. | 01-13-2011 |
| 20110053843 | E-SELECTIN COMPOSITIONS AND USE THEREOF FOR INDUCING E-SELECTIN TOLERANCE - The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia. | 03-03-2011 |
| 20110124561 | USE OF A NEUREGULIN TO TREAT PERIPHERAL NERVE INJURY - Embodiments of the invention are directed to use of neuregulins to prevent or treat peripheral nerve injury, to attenuate, ameliorate or avoid the loss of peripheral nerve function. | 05-26-2011 |
| 20110144015 | METHODS FOR TREATING MUSCLE DISEASES AND DISORDERS - The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185 | 06-16-2011 |
| 20110166068 | Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure - The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects. | 07-07-2011 |
| 20110190204 | Taxane- and Taxoid-Protein Compositions - Compositions comprising a taxane or taxoid, such as paclitaxel, and a protein, such as albumin or a metal-transferrin, such as gallium-transferrin, can be prepared by combining an aqueous protein solution with a second solution containing the taxane or taxoid, a non-ionic surfactant, and an alcohol; adjusting the pH of the combined solutions to between about 7.9 and about 8.3; and purifying the pH-adjusted solution to remove solutes having a molecular weight less than 10,000 Da. Such compositions can be prepared that are substantially free of non-ionic surfactants, such as Cremophor EL, and are useful in the treatment of cancers, such as breast cancer. | 08-04-2011 |
| 20110269682 | Compositions and Methods for Treatment During Non-Acute Periods Following CNS Neurological Injury - This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury. | 11-03-2011 |
| 20110275566 | METHODS OF TREATING NECROTIZING ENTEROCOLITIS USING HEPARIN BINDING EPIDERMAL GROWTH FACTOR (HB-EGF) - Methods of treating, abating and reducing the risk for necrotizing enterocolitis (NEC) in an infant are disclosed. Preferred methods include administering an EGF receptor agonist, such as HB-EGF or EGF, within 24 hours following birth or following the onset of at least one symptom of NEC, in an amount effective to reduce the onset or seventy of NEC. | 11-10-2011 |
| 20120040900 | COMPOSITIONS OF AND METHODS OF USING LIGAND DIMERS - Provided herein are ligand dimers, compositions thereof, as well as methods of their use. The ligand dimers provided can comprise at least one ligand to a Her receptor and can be used to force dimerization of specific receptor pairs. The forced dimerization of specific receptor pairs can be used to control (e.g., promote or inhibit) signaling, and, therefore, the ligand dimers provided can also be used in various forms of treatment in which such signaling control is beneficial to a subject. It follows that methods for controlling signaling are provided as are various methods of treatment. | 02-16-2012 |
| 20120065130 | METHODS FOR TREATING CONGESTIVE HEART FAILURE - The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene. | 03-15-2012 |
| 20120190622 | INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR-HEAT SHOCK PROTEIN 90 BINDING INTERACTION - Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy. | 07-26-2012 |
| 20120232010 | Compositions and Methods for Treating Bladder Cancer - The present invention provides methods and compositions for treating bladder cancer. In particular, the present invention provides a fusion protein comprising a toxin moiety that is linked to an epithelial growth factor (EGF) moiety. The toxin moiety and the EGF moiety can be linked optionally via a linker. Typically, the fusion protein is administered intravesically into the cancerous bladder. | 09-13-2012 |
| 20130005653 | POLYPEPTIDES - This invention relates to polypeptides which bind to EGFR family receptors and to applications of those polypeptides in medicine, veterinary medicine, diagnosis diagnostics and imaging. | 01-03-2013 |
| 20130053314 | Mutant Epidermal Growth Factor Polypeptides with Improved Biological Activity and Methods of Their Making and Use - Compositions that are EGF polypeptides that possess improved biological activity as compared to the biological activity exhibited by wild-type EGF are provided. Also provided are methods for the preparation of these mutants, methods for the use of these mutants, methods for rationally designing new polypeptide mutants, and methods for screening mutants polypeptides to identify novel EGF mutants with desirable biological activities. | 02-28-2013 |
| 20130079281 | NEUREGULIN BASED METHODS FOR TREATING HEART FAILURE - The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe. | 03-28-2013 |
| 20130102532 | HB-EGF Composition and Use Thereof to Treat a Condition Associated With Enhanced Urothelium Permeability - HB-EGF is exploited to treat conditions associated with enhanced urothelium permeability, including interstitial cystitis. | 04-25-2013 |
| 20130130984 | Administration Of Heparin Binding Epidermal Growth Factor For The Protection Of Enteric Neurons - The invention provides for methods of protecting neurons within the enteric nervous system (ENS) comprising administering an EGF receptor agonist, such as heparin-binding EGF (HB-EGF). These methods include reducing damage of ENS neurons in patient s suffering from an intestinal injury. In addition, the invention provides for increasing intestinal motility in a patient suffering from an intestinal injury comprising administering HB-EGF. The invention also provides for methods of inducing neurite growth within the ENS in a patient suffering from intestinal injury comprising administering HB-EGF. | 05-23-2013 |
| 20130165376 | Heparin Binding Epidermal Growth Factor (HB-EGF) for Use in Methods of Treating and Preventing Intestinal Injury Related to Hemorrhagic Shock and Resuscitation - The invention is related to methods of protecting, preventing and reducing intestinal injury in a human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation (HS/R) comprising administering heparin binding epidermal growth factor (HB-EGF). The invention is also related to methods of inhibiting deterioration of intestinal blood flow and methods of preserving and increasing intestinal blood flow by administering HB-EGF to a human subject. In addition, the methods of the invention should improve the clinical outcome of human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation. | 06-27-2013 |
| 20130196911 | METHODS AND COMPOSITIONS FOR CARDIOPROTECTION AND CARDIOREGENERATION - The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue. | 08-01-2013 |
| 20130244935 | Methods of Treating Necrotizing Enterocolitis Using Heparin Binding Epidermal Growth Factor - Methods of treating, abating and reducing the lisk for necrotizing enterocolitis (NEC) in an infant are disclosed. Preferred methods include admmistering an EGF receptor agonist, such as HB-EGF or EGF, within 24 hours following birth or following the onset of at least one symptom of NEC, in an amount effective to reduce the onset or seventy of NEC. | 09-19-2013 |
| 20130281372 | METHODS TO ENHANCE RNAI OLIGONUCLEOTIDE DELIVERY TO RESPIRATORY EPITHELIAL CELLS - The present invention relates to methods of reducing a level of a target mRNA in a well-differentiated airway epithelial cell by contacting the cell with a sensitizing agent followed by contacting the cell with a therapeutic RNAi agent. | 10-24-2013 |
| 20130324466 | Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Prophylaxis of Heart Failure - The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects. | 12-05-2013 |
| 20130331326 | METHOD OF INDUCING HEMATOPOIETIC RECONSTRUCTION - The present invention relates, in general, to hematopoietic reconstruction and, in particular, to a method of inducing hematopoietic reconstruction using EGF. The invention also relates to compounds and compositions suitable for use in such a method. | 12-12-2013 |
| 20140121163 | MFG-E8 AND USES THEREOF - Methods of treating cerebral ischemia using milk fat globule epidermal growth factor-factor VIII (MFG-E8) are disclosed, as are recombinant human MFG-E8 and its uses in pharmaceutical compositions, products and methods for treating inflammation and organ injury after ischemia/reperfusion, sepsis, and lung injury. | 05-01-2014 |
| 20140221289 | Thixotropic A-Lactalbumin Hydrogels, Method for Preparing Same and Uses Thereof - The present invention relates to shear-thinning α-lactalbumin hydrogels, which have a threshold and are thixotropic, to a method for preparing same and to the use thereof. | 08-07-2014 |
| 20140243268 | ERBB2 Peptides - Compositions that inhibit or block the interaction between Erbin and ErbB2 and methods of their use are provided. Preferred compositions include peptides that inhibit or block Erbin and ErbB2 interaction under physiologic conditions in a subject. One embodiment provides an isolated peptide fragment of ErbB2 including the C-terminal 15 amino acids of ErbB2. The peptide fragment can be about 15 to 27 amino acids in length. | 08-28-2014 |
| 20140243269 | METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS - Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication for effecting neuroprotection in a subject suffering from schizophrenia, bipolar disorder, depression, Alzheimer's disease, epilepsy, multiple sclerosis (MS), Amylotrophic Lateral Sclerosis (ALS), stroke, traumatic brain injury, and/or spinal cord injury. | 08-28-2014 |
| 20140243270 | PHARMACEUTICAL COMPOSITION CONTAINING NEUREGULIN ISOFORMS - A pharmaceutical composition containing a soluble Neuregulin-1 isoform representing Posttranslational Neuregulin-1 modifications. | 08-28-2014 |
| 20140357559 | Interpenetrating Polymer Network Hydrogel - A strain-hardened interpenetrating polymer network (IPN) hydrogel is provided. The interpenetrating polymer network hydrogel is based on two different networks. The first network is a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups. The second network is a non-silicone network of ionizable monomers. The second network has been polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. An aqueous salt solution having a neutral pH is used to ionize and swell the second network in the interpenetrating polymer network. The swelling of the second network is constrained by the first network, and this constraining effect results in an increase in effective physical cross-links within the interpenetrating polymer network, and, in turn, an increase its elastic modulus. The strain-hardened interpenetrating polymer network hydrogel is attractive and useful for medical, industrial, and personal hygiene purposes. | 12-04-2014 |
| 20140364365 | Mask for Skin Care - A mask for skin care includes a fiber substrate, wherein the fiber substrate is woven or nonwoven, and includes modified fibers, and the modified fibers are cellulose fibers with at least one hydrophilic functional group grafted on. The grafted ratio of the modified fibers is in the range from 5% to 30%, and the modified fibers can effectively improve the moisture absorption and the moisture-retaining capacity of the mask for skin care. | 12-11-2014 |
| 20140364366 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE - The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin. | 12-11-2014 |
| 20150031611 | Highly Stabilized Epidermal Growth Factor Mutants - There are provided mutants prepared by changing a DNA base sequence and an amino acid sequence of an epidermal growth factor (EGF), in which a mutant EGF protein has excellent thermal stability and stability even in the state of an aqueous solution, and a gene encoding the protein are provided; a recombinant vector including the gene and a microorganism transformed by the recombinant vector are provided; a method of preparing the mutant EGF protein is provided; a cosmetic composition for accelerating the growth of skin cell and skin regeneration, including the protein, the gene, or the recombinant vector, is provided; and by preparing a product using the EGF mutant according to the present invention, it is possible to produce functional cosmetics, in which the activity thereof is maintained even during a distribution and storage process unlike the conventional wild-type EGF product. | 01-29-2015 |
| 20150031612 | Allosteric Modulators of EGFR and Constitutively Active Mutants - The present invention includes a novel class of allosteric modulators that target a protein having a juxtamembrane segment. In another embodiment, the allosteric modulator is a peptide mimetic that is capable of interacting with an α-helix or a coiled coil domain of a protein. In one embodiment, the peptide mimetic binds to at least an α-helix or a coiled coil domain of EGFR and modulates its activity. | 01-29-2015 |
| 20150080304 | TREATMENT AND PREVENTION OF RADIATION INJURY USING MFG-E8 - Methods and compositions are disclosed for treating and preventing radiation injury using milk fat globule epidermal growth factor-factor VIII (MFG-E8). | 03-19-2015 |
| 20150307578 | COMPOSITION FOR LONG-ACTING PEPTIDE ANALOGS - The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm) | 10-29-2015 |
| 20160017432 | PHARMACEUTICAL COMPOSITION FOR TREATING MUSCLE-INVASIVE BLADDER CANCER, CONTAINING S100A9 AND EGFR INHIBITORS AND CISPLATIN AS ACTIVE INGREDIENTS - The present invention relates to a method for predicting the probability of muscle-invasive bladder cancer (MIBC) recurrence or metastasis, a method for providing information on a personalized medicine of MIBC, and a pharmaceutical composition for treating MIBC, containing S100A9 and EGFR inhibitors and cisplatin as active ingredients. According to the present invention, it is possible to accurately predict a prognosis after chemotherapy of an MIBC patient, to provide information on cisplatin sensitivity in the provision of a personalized medicine for chemotherapy of an MIBC patient, and to increase the cisplatin sensitivity of an MIBC patient by concomitantly administering S100A9 and EGFR inhibitors together with a conventional cisplatin. | 01-21-2016 |
| 20160074476 | Modulation of Heparin-binding Epidermal Growth Factor Activity for Tympanic Membrane Healing - Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity. | 03-17-2016 |
| 20160089329 | EXTENDED RELEASE OF NEUREGULIN FOR TREATING HEART FAILURE - The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump. | 03-31-2016 |
| 20160113998 | Methods for Treating Congestive Heart Failure - The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene. | 04-28-2016 |
| 20160113999 | Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Prophylaxis of Heart Failure - The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects. | 04-28-2016 |
| 20160129084 | Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure - The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects. | 05-12-2016 |
| 20170232068 | Methods and Compositions of Neuregulins for Preventing, Treating or Delaying Preserved Ejection Fraction Cardiac Failure | 08-17-2017 |
